A U.S. health advisory committee reviewed the Johnson & Johnson COVID-19 vaccine. This review was prompted by reports of a very rare but serious blood clotting condition called Thrombosis with Thrombocytopenia Syndrome (TTS) in some people who received the vaccine. The committee's job was to weigh the known benefits of the vaccine against this new safety concern.
The committee focused on the vaccine's use in adults aged 18 and older. After their assessment, they decided that the benefits of offering the vaccine—primarily protection against severe COVID-19—continue to be greater than the risks for most people. This means the vaccine remains available under its current emergency authorization.
However, because of the clotting reports, health officials have added a new warning. The risk of TTS appears to be highest in women between 18 and 49 years old. This update is a standard part of monitoring vaccine safety. It provides clearer information for people and their doctors to consider when choosing a vaccine, but it does not change the overall conclusion that vaccination is important.